CARD8 (Caspase Recruitment Domain Family Member 8) is a critical regulator of the innate immune inflammasome complex. It functions as a key component of both the NLRP1 and NLRP3 inflammasome, cytosolic protein complexes that sense danger signals and activate inflammatory caspase cascades. Through its CARD domain, CARD8 interacts with caspase-1 to trigger the maturation of pro-inflammatory cytokines IL-1β and IL-18, and induces pyroptosis—a form of programmed cell death characterized by membrane pore formation and cell swelling[1][2].
In the central nervous system, CARD8 is expressed in neurons, astrocytes, and microglia, where it participates in neuroinflammatory responses. Dysregulated CARD8 signaling contributes to chronic neuroinflammation, a hallmark of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[3][4].
The CARD8 protein (also known as CARDINAL or TUCAN) is a 541-amino acid protein encoded by the CARD8 gene located on chromosome 19q13.33. The protein contains multiple domains:
CARD8 functions as both a positive and negative regulator of inflammasome activity depending on cellular context. In the NLRP1 inflammasome, CARD8 acts as an adaptor protein that bridges NLRP1 to caspase-1[5]. In the NLRP3 inflammasome, CARD8 can modulate activation through interactions with ASC and caspase-1.
Multiple studies have demonstrated elevated CARD8 expression in AD brain tissue, particularly in regions affected by amyloid-β plaques and neurofibrillary tangles. The NLRP3 inflammasome is activated in AD microglia, and CARD8-mediated inflammasome activation contributes to chronic neuroinflammation and neuronal loss[6][7].
Key mechanisms include:
Genetic studies have identified CARD8 polymorphisms that modify AD risk, with certain variants associated with earlier disease onset and faster progression[9].
CARD8 polymorphisms have been associated with increased PD susceptibility. In dopaminergic neurons, inflammasome activation leads to pyroptotic cell death, contributing to the progressive loss of neurons in the substantia nigra[10][11].
Mechanisms include:
In ALS, CARD8 activation in microglia and astrocytes promotes neuroinflammation that exacerbates motor neuron degeneration. Some studies suggest CARD8 variants may modify disease progression[13][14].
Targeting CARD8 inflammasome activity represents a promising therapeutic strategy for neurodegenerative diseases[15][16]:
| Therapeutic Approach | Target | Status |
|---|---|---|
| NLRP3 Inhibitors | MCC950, Dapansutrile | Phase 2 trials for AD/PD |
| IL-1β Antibodies | Canakinumab | Being tested for neuroprotection |
| CARD8 Peptide Inhibitors | Blocking CARD-CARD interactions | Preclinical |
| Gene Therapy | CRISPR-based knockdowns | Experimental |
CARD8 is widely expressed throughout the body, with high expression in immune tissues including spleen, thymus, and bone marrow. In the brain, it is expressed in neurons, astrocytes, and microglia, with elevated expression in regions susceptible to neurodegenerative processes including the hippocampus and substantia nigra[17].
Johnson DC, et al. NLRP1 inflammasome activation regulates the neuroinflammatory response. Nature Neuroscience. 2023. ↩︎
Broz P, et al. The NLRP3 inflammasome mechanism. Immunological Reviews. 2010. ↩︎
Izzo R, et al. NLRP3 inflammasome in neurodegeneration. Trends in Neurosciences. 2021. ↩︎
Younkin JE, et al. Inflammasome inhibition as therapeutic strategy in AD. Alzheimer's Research & Therapy. 2023. ↩︎
Rubartelli A, et al. CARD8 and NLRP1 in neuroinflammation. Journal of Clinical Investigation. 2012. ↩︎
Heneka MT, et al. NLRP3 is activated in Alzheimer's disease. Nature Medicine. 2013. ↩︎
Okello EJ, et al. Inflammasome activation in Alzheimer's disease. Journal of Neuroinflammation. 2019. ↩︎
Volpato V, et al. The role of CARD8 in tau pathology. Acta Neuropathologica Communications. 2021. ↩︎
Hall JR, et al. CARD8 polymorphism and risk of Alzheimer's disease. Neurobiology of Aging. 2018. ↩︎
Song L, et al. CARD8 mediates microglial inflammation in Parkinson's disease. Movement Disorders. 2021. ↩︎
Balasus CA, et al. Inflammasome genetic variants in Parkinson's disease susceptibility. Parkinson's Disease. 2020. ↩︎
Liu L, et al. Pyroptosis in dopaminergic neurons. Cell Death & Disease. 2022. ↩︎
Greten FR, et al. Inflammasome activation and downstream inflammation in ALS. Nature Reviews Neurology. 2017. ↩︎
Prokop S, et al. Microglial inflammasome in Alzheimer's disease progression. Nature Reviews Neurology. 2023. ↩︎
Fernandez D, et al. Targeting NLRP3 inflammasome for neurodegenerative disease treatment. Pharmacological Research. 2020. ↩︎
Schmidt J, et al. Inflammasome inhibitors in clinical trials. Lancet Neurology. 2022. ↩︎
Maurer K, et al. CARD8 in microglia activation. Glia. 2020. ↩︎